Bell Potter issued a update note on MYX on 14th Apr'21 and based on Nextstellis FDA approval it has a 12 month price target of $0.56
A quote from the report as follows....Nextstellis represents the largest single product revenue opportunity for MYX in the company’s history....
The report also goes on to say that the safety aspects of Nextstellis if proven in a new longitudinal study it may lead to further intellectual property protection
......POST APPROVAL SAFETY STUDY
The safety aspect of Nextstellis potentially represents a potential sustainable competitive advantage over competing products. As was the case for Twirla’s approval, the FDA is likely to requiring Mayne Pharma/Mithra to conduct a long-term prospective, observational post-marketing study comparing the risks for venous thromboembolism (VTE) and arterial thromboembolism (ATE) in new users of Nextstellis4 . This requirement is not unusual. While the conduct of such a study is arduous taking years to complete, it is likely the cost would be met by Mithra. The provision of this data may provide further grounds for extension of IP protection
The future may perhaps be getting better for MYX though the share price action is not reflecting my optimism.
MYX Price at posting:
39.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)